Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Gabriel Gomis
Institutions:
Navarre Institute of Health Research,
Clinica Universidad de Navarra,
Centro de Investigación Médica Aplicada
Observed institutions:
Navarre Institute of Health Research,
Clinica Universidad de Navarra,
Centro de Investigación Médica Aplicada,
Universidad de Navarra
ORCID:
0000-0003-4361-3328
Observed ORCID:
0000-0003-4361-3328
OpenAlex ID:
A5064625277
Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps
2024
·
Alvaro Teijeira
, Saray Garasa
, et al.
·
Clinical Cancer Research
·
33
Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
2023
·
Ignacio Melero
, Maria C Ochoa
, et al.
·
EMBO Molecular Medicine
·
28
PDF
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming
2023
·
Carlos Luri‐Rey
, Gabriel Gomis
, et al.
·
Immunological Reviews
·
24
Immunocytokines and cytokine neutralization for cancer immunotherapy
2025
·
Pedro Berraondo
, Raquel Cuesta
, et al.
·
Trends in cancer
·
23
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
2023
·
Maite Alvarez
, Carmen Molina
, et al.
·
OncoImmunology
·
17
CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects
2023
·
Javier Glez-Vaz
, Arantza Azpilikueta
, et al.
·
Science Advances
·
12
PDF
Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists
2023
·
Assunta Cirella
, Elixabet Bolaños
, et al.
·
Molecular Therapy — Nucleic Acids
·
10
Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism
2024
·
Iñaki Eguren-Santamaría
, Inmaculada Rodríguez
, et al.
·
OncoImmunology
·
6
The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy
2024
·
Pedro Berraondo
, Gabriel Gomis
, et al.
·
Cancer Cell
·
6
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
·
Clinical Cancer Research
·
5
Facts and Hopes on Neutralization of Protumor Inflammatory Mediators in Cancer Immunotherapy
2023
·
Irene Olivera
, Carlos Luri-Rey
, et al.
·
Clinical Cancer Research
·
5
Cross-priming underlies the efficacy of antibody–drug conjugates and immunotherapy combinations
2026
·
Gabriel Gomis
, Pedro Berraondo
, et al.
·
Trends in Immunology
·
2
T cell cross-priming by PD-L1+ type 1 conventional dendritic cells mediates the antitumor efficacy of a PD-L1×4-1BB bispecific antibody
2026
·
Carlos Luri-Rey
, Inmaculada Rodríguez
, et al.
·
Immunity
·
1
PDF
Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
2026
·
Gabriel Gomis
, Claudia Herrero
, et al.
·
Cancer Research
·
1
TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment
2026
·
Elixabet Bolaños
, Lorena Cañas-Zabala
, et al.
·
The Journal of Experimental Medicine
·
1
PDF
Monomethyl-auristatin E-based anti-CD137 (4-1BB) antibody drug conjugates are not suitable tools to deplete activated T lymphocytes
2026
·
Gabriel Gomis
, Saioa Arrieta-Aranzueque
, et al.
·
Immunobiology
·
1
Neutrophil extracellular traps and cancer immune-escape
2025
·
Beatrice Pinci
, Almudena Manzanal
, et al.
·
Elsevier eBooks
·
1
Supplementary Fig. S7 from Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
2026
·
Gabriel Gomis
, Claudia Herrero
, et al.
Supplementary Fig. S3 from Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
2026
·
Gabriel Gomis
, Claudia Herrero
, et al.
Supplementary Fig. S1 from Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
2026
·
Gabriel Gomis
, Claudia Herrero
, et al.
Supplementary Fig. S2 from Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
2026
·
Gabriel Gomis
, Claudia Herrero
, et al.
Supplementary Fig. S5 from Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
2026
·
Gabriel Gomis
, Claudia Herrero
, et al.
Supplementary Fig. S11 from Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
2026
·
Gabriel Gomis
, Claudia Herrero
, et al.
Supplementary Fig. S4 from Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
2026
·
Gabriel Gomis
, Claudia Herrero
, et al.
Supplementary Fig. S10 from Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
2026
·
Gabriel Gomis
, Claudia Herrero
, et al.
Show more works
View as search
Works count:
53
Citation count:
176
H-index:
7
I10-index:
7
Year
Topic
Type